Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Friday 17 February, 2017

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 2287X
GlaxoSmithKline PLC
17 February 2017
 

GlaxoSmithKline plc (the 'Company')

 

Conditional Share Awards

This notification sets out the vesting details of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares made in 2014 under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (DABP) and the associated Matching Awards, which were subject to relevant business performance conditions.  The three-year performance period for the 2014 awards commenced on 1 January 2014 and ended on 31 December 2016 and the restricted period has come to an end. 

The performance measure vesting details are as follows:

Portion of the Award

Measure

Outcome

Overall outcome

1/3rd

Adjusted free cash flow - The Company did not meet the threshold level of performance for adjusted free cash flow for the three year period.

Lapsed in full

0%

1/3rd

TSR measure - For the three years ending 31 December 2016, the Company's TSR ranked 9th (i.e. below median) against a comparator group of 10 global pharmaceutical companies including GSK.

Lapsed in full

0%

1/3rd

R&D New Products sales measure - For the three year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of £6.717bn, which was above the maximum vesting level of £4.428bn (the threshold level was £3.623bn) after appropriate adjustments for the implications of the three-part transaction with Novartis.

Vested in full

33.33%

 

Total vesting for 2014 award

Lapsed

33.33%

66.67%

 

The notifications that follow are for awards made to Persons Discharging Managerial Responsibilities (PDMRs) and show the vesting of the Deferred Bonus Awards including dividends accrued and the proportion of the Matching Awards i.e., conditional awards that vested including dividends accrued on the awards which vested in the same proportion, subject to performance, as the underlying shares on 16 February 2017. The balance of these awards made to each PDMR has lapsed.

The closing prices of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 16 February 2017 were £16.17 and $40.92 respectively.

 

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Andrew Witty

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

67,867 (Deferred)

£0.00

22,621 (Matching)

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

                                                                                           90,488      

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms Emma Walmsley

b)

Position/status

CEO Designate

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

14,860 (Deferred)

£0.00

4,954 (Matching)

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

                                                                                           19,814    

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

13,284 (Deferred)

£0.00

4,428 (Matching)

 

d)

Aggregated information

 

 

Aggregated volume

 

Price

 

 

17,712

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

22,448 (Deferred)

£0.00

7,483 (Matching)

 

d)

Aggregated information

 

 

Aggregated volume

 

Price

 

 

29,931  

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S A Hussain

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

9,743 (Deferred)

£0.00

3,248 (Matching)

 

d)

Aggregated information

 

 

Aggregated volume

 

Price

 

 

12,991   

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

12,115 (Deferred)

£0.00

4,039 (Matching)

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

                                                                                           16,154                                                                                 

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr M M Slaoui

b)

Position/status

Chairman, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

  

b)

Nature of the transaction

The number of ADSs released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan--Deferred Bonus and Matching Awards.

 

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$0.00

21,645 (Deferred)

$0.00

7,215 (Matching)

 

 

 

d)

Aggregated information

 

Aggregated volume

 

Price

 

                                                                                                         

28,860 

$0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

7,517 (Deferred)

£0.00

2,506 (Matching)

 

d)

Aggregated information

 

 

Aggregated volume

 

Price

 

 

10,023   

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

SVP, Communications & Government Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

  

 

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

4,528 (Deferred)

£0.00

1,509 (Matching)

 

d)

Aggregated information

 

 

Aggregated volume

 

Price

 

                                                         

6,037

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

  

 

b)

Nature of the transaction

The number of ADSs released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan--Deferred Bonus and Matching Awards.

 

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$0.00

8,762 (Deferred)

$0.00

2,920 (Matching)

 

 

 

d)

Aggregated information

 

Aggregated volume Price

 

                                                                                                         

11,682                                                                                       $0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President,  R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

  

b)

Nature of the transaction

The number of Ordinary Shares released on awards granted in 2014 under the Company's 2009 Deferred Annual Bonus Plan-Deferred Bonus and Matching Awards.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£0.00

26,863 (Deferred)

£0.00

8,954 (Matching)

 

d)

Aggregated information

 

 

Aggregated volume

 

Price

 

  

35,817

£0.00

e)

Date of the transaction

2017-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEDLFFDLFEBBX

a d v e r t i s e m e n t